Acute Undifferentiated Leukemia
Description
This dataset fills a critical gap in published AUL evidence: prior studies only document venetoclax–azacitidine dual therapy, while no public clinical data exists for the triple regimen (azacitidine + venetoclax + sorafenib) in patients with dual FLT3 missense mutations. All uploaded tables contain granular cycle-by-cycle drug doses, early drug discontinuation timelines and full supportive medication records (G-CSF, eltrombopag, anti-infectives), details condensed within the original manuscript. Researchers may reuse this dataset for two core analyses: Compare this case’s unique immunophenotype with MPAL/AML-M0 using the full flow cytometry panel; Pool the FLT subclonal mutation data with existing cohorts to analyze outcomes of non-ITD FLT3 variants. Serial MRD records offer real-world reference for MRD-guided dose de-escalation in elderly unfit leukemia patients. All images have been fully de-identified: hospital watermarks, specimen barcodes and sampling timestamps are cropped completely. No data can be cross-matched to inpatient archives, fully complying with institutional ethics rules and the Declaration of Helsinki. The CC-BY 4.0 license allows non-commercial academic reuse, provided users cite both the original manuscript and this dataset DOI. Key interpretative reminders: Permanent megakaryocyte loss is a combined toxic effect of three myelosuppressive agents, not sorafenib alone. Readers must differentiate transient post-cycle cytopenia from irreversible marrow hypoplasia shown on follow-up bone marrow slides. Restrictions apply to raw NGS fastq files and full electronic medical records per local human genetic regulations. Researchers needing unprocessed sequencing data must submit a formal request with institutional ethical certification and a non-commercial data use agreement to the corresponding author. Any attempt to trace patient identity or utilize these data for commercial research is prohibited.
Files
Steps to reproduce
Steps to reproduce all dataset findings Diagnostic specimen collection & testing (Baseline) Collect bone marrow aspirate from the patient at initial presentation; perform Wright-Giemsa and POX staining for morphological slides, capture digital micrographs under standard laboratory light microscopy. Run standardized 32-color flow cytometry lineage panel on marrow nucleated cells via BD FACSCanto II to identify blast immunophenotype. Extract variant data using 256-gene hematological tumor NGS panel (average depth ≥1000×) and capillary electrophoresis for FLT3-ITD detection. Compile all variant results into a standardized Excel table. Triple targeted therapy administration Administer azacitidine, venetoclax and sorafenib following the documented cycle-based dosing scheme. Adjust venetoclax duration and azacitidine dosage in subsequent cycles when Grade 4 myelosuppression emerges; record all supportive care medications (G-CSF, thrombopoietic agents, anti-infectives). Document early drug discontinuation timelines triggered by severe cytopenia. Cycle-based efficacy & safety monitoring After each treatment cycle, repeat bone marrow morphology assessment and flow cytometry MRD detection; track serial peripheral blood counts and FLT3-ITD quantitative tests across all follow-up phases. Record persistent megakaryocyte loss and infectious adverse events in longitudinal clinical tables. Data de-identification & dataset sorting Remove all exact calendar dates, hospital watermarks, specimen IDs and personal identifiers from images and tables; replace time points with relative treatment phases (Baseline / Cycle 1 / Cycle 2 / Cycle 3 / Post-treatment). Organize anonymized cytology images, flow plots and all tabular source data into a unified open dataset for public deposition. Result reproduction guidance To replicate the study conclusions: Compare blast markers against 2022 WHO AUL diagnostic criteria using the provided flow and cytology images; Cross-reference NGS variant VAF values to confirm dual FLT3 missense subclonal mutations; Match cycle dosing records with sequential MRD and marrow histology data to assess remission depth and long-term myelotoxicity. Data access for full raw materials Unprocessed DICOM and NGS fastq files are not publicly available. Researchers who wish to reproduce full raw sequencing/imaging analysis must submit an ethical-approved data request to the corresponding author for restricted material access.